Abiraterone acetate and prednisolone for metastatic castration‐resistant prostate cancer failing androgen deprivation and docetaxel‐based chemotherapy: A phase <scp>II</scp> bridging study in <scp>K</scp>orean and <scp>T</scp>aiwanese patients
Cheol Kwak(Seoul National University Hospital), Choung‐Soo Kim(Asan Medical Center), Hyou Young Rhim(Janssen (United States)), Thian Kheoh(Janssen (United States)), Ying Wan(Geron (United States)), Sung Joon Hong(New Generation University College), Margaret K. Yu(Boston Biomedical (United States)), Tony T. Wu(Kaohsiung Veterans General Hospital), Yen Chuan Ou(Taichung Veterans General Hospital), Hsi Chin Wu(China Medical University), Seok‐Soo Byun(Seoul National University Bundang Hospital), Howard Yeh(Hospital de Santa Maria), Hyun Moo Lee(Samsung Medical Center)
Cited by 12
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k